Last reviewed · How we verify

Amodiaquine+Sulfadoxine/Pyrimethamine

University of California, San Francisco · Phase 3 active Small molecule

Amodiaquine+Sulfadoxine/Pyrimethamine is a Antimalarial combination Small molecule drug developed by University of California, San Francisco. It is currently in Phase 3 development for Uncomplicated Plasmodium falciparum malaria, Malaria treatment in endemic regions.

This combination drug inhibits parasite dihydrofolate reductase and dihydropteroate synthase enzymes while disrupting parasite hemoglobin metabolism to treat malaria.

This combination drug inhibits parasite dihydrofolate reductase and dihydropteroate synthase enzymes while disrupting parasite hemoglobin metabolism to treat malaria. Used for Uncomplicated Plasmodium falciparum malaria, Malaria treatment in endemic regions.

At a glance

Generic nameAmodiaquine+Sulfadoxine/Pyrimethamine
SponsorUniversity of California, San Francisco
Drug classAntimalarial combination
TargetParasite dihydrofolate reductase, dihydropteroate synthase, hemoglobin metabolism
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Amodiaquine is a 4-aminoquinoline that disrupts malaria parasite hemoglobin digestion and generates reactive oxygen species. Sulfadoxine/Pyrimethamine is a fixed-dose combination that inhibits sequential steps in parasite folate synthesis, blocking dihydropteroate synthase and dihydrofolate reductase. Together, these agents provide synergistic antimalarial activity through complementary mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Amodiaquine+Sulfadoxine/Pyrimethamine

What is Amodiaquine+Sulfadoxine/Pyrimethamine?

Amodiaquine+Sulfadoxine/Pyrimethamine is a Antimalarial combination drug developed by University of California, San Francisco, indicated for Uncomplicated Plasmodium falciparum malaria, Malaria treatment in endemic regions.

How does Amodiaquine+Sulfadoxine/Pyrimethamine work?

This combination drug inhibits parasite dihydrofolate reductase and dihydropteroate synthase enzymes while disrupting parasite hemoglobin metabolism to treat malaria.

What is Amodiaquine+Sulfadoxine/Pyrimethamine used for?

Amodiaquine+Sulfadoxine/Pyrimethamine is indicated for Uncomplicated Plasmodium falciparum malaria, Malaria treatment in endemic regions.

Who makes Amodiaquine+Sulfadoxine/Pyrimethamine?

Amodiaquine+Sulfadoxine/Pyrimethamine is developed by University of California, San Francisco (see full University of California, San Francisco pipeline at /company/university-of-california-san-francisco).

What drug class is Amodiaquine+Sulfadoxine/Pyrimethamine in?

Amodiaquine+Sulfadoxine/Pyrimethamine belongs to the Antimalarial combination class. See all Antimalarial combination drugs at /class/antimalarial-combination.

What development phase is Amodiaquine+Sulfadoxine/Pyrimethamine in?

Amodiaquine+Sulfadoxine/Pyrimethamine is in Phase 3.

What are the side effects of Amodiaquine+Sulfadoxine/Pyrimethamine?

Common side effects of Amodiaquine+Sulfadoxine/Pyrimethamine include Nausea, Vomiting, Abdominal pain, Headache, Pruritus, Stevens-Johnson syndrome (rare).

What does Amodiaquine+Sulfadoxine/Pyrimethamine target?

Amodiaquine+Sulfadoxine/Pyrimethamine targets Parasite dihydrofolate reductase, dihydropteroate synthase, hemoglobin metabolism and is a Antimalarial combination.

Related